SRK-439

About Scholar Rock

Scholar Rock is a biopharmaceutical company dedicated to discovering, developing, and delivering innovative therapies for serious diseases by targeting protein growth factors in their latent, inactive state. Its most advanced asset, apitegromab, has shown promising Phase 3 results in spinal muscular atrophy (SMA) and is being evaluated in cardiometabolic disorders. The company's strategy leverages its unique scientific platform to build a pipeline across multiple therapeutic areas with high unmet need, positioning it for potential near-term commercialization and long-term growth.

About Scholar Rock Holding

Scholar Rock is a clinical-stage biopharmaceutical company founded on a paradigm-shifting scientific strategy: targeting the latent, inactive forms of growth factors, particularly within the TGFβ superfamily, to achieve precise, localized therapeutic effects. The company's most advanced asset, apitegromab, has demonstrated promising Phase 3 results in spinal muscular atrophy (SMA) and is positioned as a potential first-in-class muscle-targeted therapy. Supported by a robust proprietary platform and a strong financial position, Scholar Rock's strategy extends beyond neuromuscular diseases into cardiometabolic disorders and immuno-oncology, aiming to build a diversified portfolio of novel biologics.

Therapeutic Areas